Distinct Concentration-Dependent Effects of the Polo-like Kinase 1-Specific Inhibitor GSK461364A, Including Differential Effect on Apoptosis

被引：117

作者：

Gilmartin, Aidan G. ^{[1
]}

Bleam, Maureen R. ^{[1
]}

Richter, Mark C. ^{[1
]}

Erskine, Symon G. ^{[1
]}

Kruger, Ryan G. ^{[1
]}

Madden, Lenore ^{[1
]}

Hassler, Daniel F. ^{[1
]}

Smith, Gary K. ^{[1
]}

Gontarek, Richard R. ^{[1
]}

Courtney, Mary P. ^{[1
]}

Sutton, David ^{[1
]}

Diamond, Melody A. ^{[1
]}

Jackson, Jeffrey R. ^{[1
]}

Laquerre, Sylvie G. ^{[1
]}

机构：

[1] GlaxoSmithKline, Collegeville, PA USA

来源：

CANCER RESEARCH | 2009年 / 69卷 / 17期

关键词：

SMALL-MOLECULE INHIBITOR; SPINDLE-CHECKPOINT PROTEINS; ANAPHASE-PROMOTING COMPLEX; IN-VITRO; PLK1; CANCER; CELLS; ACTIVATION; ROLES; DISCOVERY;

D O I：

10.1158/0008-5472.CAN-09-0945

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Polo-like kinase 1 (Plk1) is a conserved serine/threonine kinase that plays an essential role in regulating the many processes involved in mitotic entry and progression. In humans, Plk1 is expressed primarily during late G(2) and M phases and, in conjunction with Cdk1/cyclin B1, acts as master regulatory kinases for the myriad protein substrates involved in mitosis. Plk1 overexpression is strongly associated with cancer and has been correlated with poor prognosis in a broad range of human tumor types. We have identified a potent, selective, reversible, ATP-competitive inhibitor of Plk1, GSK461364A, capable of inhibiting cell growth of most proliferating cancer cell lines tested. We observe distinct cell cycle effects of GSK461364A depending on the dose used, The predominant phenotype for cells treated with GSK461364A is prometaphase arrest with characteristic collapsed polar polo spindle. At high concentrations, GSK461364A delays mitotic entry in G(2) followed by gradual progression into terminal mitosis; in some cell lines, this correlates with decreased apoptosis. Cell culture growth inhibition by GSK461364A can be cytostatic or cytotoxic but leads to tumor regression in xenograft tumor models under proper dose scheduling. Finally, we describe pharmacodynamic biomarkers of GSK461364A activity (pHH3 and Plk1) that are currently being evaluated in human cancer clinical trials. [Cancer Res 2009;69(17):6969-77]

引用

页码：6969 / 6977

页数：9

共 46 条

[1]

Polo-like kinase 1 creates the tension-sensing 3F3/2 phosphoepitope and modulates the association of spindle-checkpoint proteins at kinetochores [J].